Market revenue in 2023 | USD 222.9 million |
Market revenue in 2030 | USD 214.6 million |
Growth rate | -0.5% (CAGR from 2023 to 2030) |
Largest segment | Antiemetics |
Fastest growing segment | NSAIDs and Others |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 28.22% in 2023. Horizon Databook has segmented the Brazil cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
The Brazil cancer supportive care drugs market is anticipated to decline over the forecast period. Brazilian healthcare system does not have established protocols for use of opioid and other cancer supportive care drugs. However, Brazilian Consensus on Nausea and Vomiting in Palliative Care refers to the protocol of European Society of Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC).
Additionally, there is limited availability and access to cancer pain drugs such as opioids in the public sector. On the other hand, factors such as increasing government initiatives & large target patient population are expected to drive market growth. According to a report, the Brazilian government spent around USD 8.61 billion in hospital and patient care sector in 2020.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Brazil cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account